Respiratory

COPD exacerbation: inpatient management and discharge planning

Clinical Overview and When to Suspect COPD Exacerbation

— COPD is the 4th leading cause of US death; exacerbations drive most morbidity, hospitalization cost, and lung function decline.

— ~50–70% of exacerbations are triggered by respiratory infection (viral > bacterial; common pathogens: H. influenzae, S. pneumoniae, M. catarrhalis, Pseudomonas in advanced disease).

— Non-infectious triggers: air pollution, heat/cold, nonadherence, PE (consider in 5–10%), CHF overlap.

— Known COPD or ≥10 pack-year smoker with acute change in baseline dyspnea, sputum volume, or sputum purulence (Anthonisen criteria).

— Increased rescue inhaler use, accessory muscle use, hypoxemia, hypercapnia, altered mental status.

— New peripheral edema may indicate cor pulmonale exacerbation.

— Mild: SABA only.

— Moderate: SABA + antibiotics and/or oral corticosteroids.

— Severe: ED visit or hospitalization; consider respiratory failure if PaCO₂ >45 with pH <7.35 or PaO₂ <60 on room air.

Board pearl: A COPD patient with new exacerbation but clear chest, normal CXR, and unilateral leg swelling — order CT pulmonary angiography; PE prevalence in unexplained COPD exacerbations is up to ~16%. Don't anchor on "just an exacerbation."

Step 3 management: First decision point on the CCS — assign location of care (home vs ward vs ICU) before drug ordering.

Definition (GOLD 2024): Acute event characterized by worsening dyspnea and/or cough/sputum over <14 days, often accompanied by tachypnea/tachycardia, and associated with local and systemic inflammation due to airway infection, pollution, or other airway insult.

Epidemiology and burden:

When to suspect in the ED/admission setting:

Severity grading (GOLD):

Differential trap: Always actively exclude PE, pneumonia, pneumothorax, acute decompensated HF, and ACS — they mimic or coexist with exacerbation and change management entirely.

Presentation Patterns and Key History

— Increased dyspnea

— Increased sputum volume

— Increased sputum purulence (yellow/green color change)

— Presence of all 3 = type I; 2 = type II; 1 + minor symptom (URI, fever, wheeze, increased cough/HR/RR by 20%) = type III.

— Symptom escalation over hours to days (vs. weeks suggests progression of underlying disease, malignancy, or HF).

— Recent URI prodrome supports viral trigger (influenza, RSV, rhinovirus, SARS-CoV-2).

— Baseline functional status: mMRC dyspnea score, 6-minute walk tolerance, home O₂ use, prior intubations.

— Prior exacerbation frequency: ≥2 moderate or ≥1 severe in past year = "frequent exacerbator" phenotype — predicts recurrence and changes outpatient regimen.

— Home regimen and adherence: LABA/LAMA/ICS, nebulizer use, oxygen flow rate, CPAP/BiPAP at home.

— Smoking status including vaping/e-cigarettes; willingness to quit (frame as the single most effective intervention).

— Vaccination history: influenza (annual), pneumococcal (PCV20 or PCV15+PPSV23), COVID-19, RSV (≥60), Tdap.

— Occupational/environmental: biomass fuel, dust, recent travel.

— Hemoptysis → think malignancy, PE, bronchiectasis — not typical exacerbation.

— Pleuritic chest pain → PE or pneumothorax workup.

— Orthopnea, PND, weight gain → HF overlap; check BNP.

— Confusion/somnolence → impending hypercapnic respiratory failure.

Key distinction: Chronic bronchitis phenotype presents with sputum-dominant flares; emphysema phenotype presents with dyspnea-dominant flares with minimal sputum — antibiotic threshold is lower in the former.

CCS pearl: Document advance directives and code status within the first simulated hour — exacerbation patients can decompensate to intubation decisions quickly.

Cardinal symptoms (Anthonisen triad):

Timeline clues:

Critical history elements to elicit on admission:

Red flag history:

Physical Exam Findings and Hemodynamic Assessment

— Tripoding, pursed-lip breathing, accessory muscle use (sternocleidomastoid, scalenes) = high work of breathing.

— Inability to speak in full sentences → severe exacerbation, prepare for NIV.

— Asterixis or somnolence → hypercapnic encephalopathy.

— Tachypnea >24, HR >110, SpO₂ <88% on room air all support severe exacerbation.

— Target SpO₂ 88–92% — over-oxygenation worsens V/Q mismatch and CO₂ retention (Haldane effect).

— Fever uncommon in pure exacerbation — if present, look for pneumonia.

— Diffuse expiratory wheeze, prolonged expiratory phase, distant breath sounds.

— Silent chest = ominous — too little airflow to wheeze; prepare for intubation.

— Focal crackles → pneumonia overlay; absent breath sounds + hyperresonance → pneumothorax.

— Loud P2, parasternal heave, JVD, hepatomegaly, peripheral edema = cor pulmonale.

— Pulsus paradoxus >10 mmHg suggests severe airflow obstruction or tamponade.

— Hypotension during NIV/intubation suggests auto-PEEP / dynamic hyperinflation — disconnect bag temporarily.

— Glasgow assessment; declining mentation despite oxygen = CO₂ narcosis until proven otherwise.

Board pearl: A patient with COPD on NIV who suddenly becomes hypotensive — think auto-PEEP first (disconnect from vent, allow exhalation), then pneumothorax (urgent CXR or POCUS lung sliding).

Step 3 management: Do a focused DVT exam (calf asymmetry) on every COPD admission — it changes whether you image for PE.

CCS pearl: Repeat vitals and pulmonary exam at 1-hour intervals after starting therapy; document response — graders score serial reassessment.

General appearance:

Vitals to interpret:

Pulmonary exam:

Cardiovascular and volume:

Neurologic:

Diagnostic Workup — Initial Labs, Imaging, ECG, Biomarkers

— Obtain in any patient with severe distress, SpO₂ <92% on RA, or altered mental status.

— Respiratory acidosis (pH <7.35, PaCO₂ >45) identifies acute hypercapnic respiratory failure → NIV indication.

— Chronic compensated hypercapnia shows elevated bicarb with near-normal pH; acute-on-chronic shows pH drop with disproportionately high CO₂.

— Eosinophilia (≥300/µL) supports steroid responsiveness and informs outpatient ICS use.

— Look for hypokalemia/hypomagnesemia from β-agonist therapy.

— Polycythemia (Hct >55) suggests chronic hypoxemia.

— Troponin elevation in exacerbation is common and prognostic; rule out type 1 MI if ischemic features.

— BNP helps distinguish HF overlap (>500 favors HF; <100 argues against).

— Look for right heart strain (P pulmonale, RAD, RBBB, S1Q3T3), AFib/MAT (multifocal atrial tachycardia is classic in COPD), ischemia.

— Rule out pneumonia, pneumothorax, pulmonary edema, mass, effusion.

— Hyperinflation with flattened diaphragms and increased retrosternal air space supports COPD baseline.

— Gram stain/culture if severe exacerbation, ICU admission, frequent exacerbator, or risk for Pseudomonas (FEV₁ <50%, recent antibiotics/steroids, prior isolation, bronchiectasis).

Board pearl: Multifocal atrial tachycardia (≥3 distinct P-wave morphologies, rate >100) is the COPD-associated arrhythmia — treat the hypoxemia and electrolytes, not with cardioversion or AV nodal blockade primarily.

CCS pearl: On the CCS, order ABG, CBC, BMP, troponin, BNP, ECG, CXR, and viral PCR as a bundle in the first action block.

ABG (arterial blood gas):

CBC, BMP, magnesium:

Troponin and BNP/NT-proBNP:

ECG:

Chest X-ray (always):

Sputum studies:

Viral PCR panel: influenza, RSV, SARS-CoV-2 — drives isolation and antiviral therapy.

Procalcitonin: May guide antibiotic duration; not required for initiation.

Diagnostic Workup — Advanced or Confirmatory Studies

— Indicated when exacerbation is unexplained, atypical, or steroid/antibiotic-refractory; sudden pleuritic pain; hemoptysis; syncope; unilateral leg swelling; elevated D-dimer adjusted for age.

— PE prevalence in hospitalized COPD exacerbations without alternative trigger is ~16%.

— Consider if recurrent exacerbations to evaluate for bronchiectasis, emphysema phenotype, mass, ILD overlap.

— Centrilobular emphysema favors smoking; panlobular lower-lobe predominant raises α1-antitrypsin deficiency.

— Order for suspected cor pulmonale, RV strain on ECG, or HF overlap.

— Assess RV size/function, PASP estimate, LV function, valvular disease.

— Do NOT perform spirometry during acute exacerbation — unreliable and may worsen distress.

— Schedule post-discharge spirometry at 4–6 weeks once stable to confirm/restage COPD (post-bronchodilator FEV₁/FVC <0.7).

— Test once in every newly diagnosed COPD patient, especially if onset <45, lower-lobe emphysema, family history, or non-smoker. WHO/ATS/ERS Class A recommendation.

— Screen for OSA overlap syndrome — STOP-BANG; overlap doubles cardiovascular mortality and changes home BiPAP decisions.

Key distinction: Spirometry confirms COPD diagnosis but is for the stable outpatient — exacerbation is a clinical diagnosis based on symptom change.

Step 3 management: Document an outpatient plan for spirometry, AAT testing if never done, and sleep evaluation if overlap suspected — Step 3 expects longitudinal planning, not just inpatient stabilization.

CT pulmonary angiography (CTPA):

High-resolution CT chest (non-contrast):

Echocardiogram:

Pulmonary function testing:

α1-antitrypsin level:

Sleep study (post-discharge):

Bronchoscopy: Reserve for suspected obstruction, atypical infection (immunosuppressed), hemoptysis workup.

Risk Stratification and First-Line Management Logic

— Outpatient management if: mild symptoms, no comorbidity decompensation, reliable home support, SpO₂ ≥90% on RA or baseline O₂, able to ambulate, no altered mentation.

— Ward admission if: moderate–severe symptoms, hypoxemia requiring escalation of home O₂, acute hypercapnia without acidosis, failed outpatient therapy, significant comorbidity (HF, CAD, DM).

— ICU admission if: severe dyspnea unresponsive to initial therapy, altered mental status, persistent/worsening hypoxemia (PaO₂ <40) or severe respiratory acidosis (pH <7.25), need for invasive ventilation, hemodynamic instability, NIV failure.

— DECAF (Dyspnea eMRCD 5a/5b, Eosinopenia <0.05, Consolidation, Acidemia pH<7.3, AFib) — score ≥3 = high mortality, consider ICU/palliative discussion.

— A — Airway and oxygen: titrate to SpO₂ 88–92% via nasal cannula or Venturi mask.

— B — Bronchodilators: SABA + SAMA nebulized (albuterol 2.5 mg + ipratropium 0.5 mg q1h × 3, then q4–6h).

— C — Corticosteroids: prednisone 40 mg PO daily × 5 days (or methylprednisolone 40 mg IV if NPO).

— S — Suspect infection: antibiotics if Anthonisen type I, purulent sputum, or mechanical ventilation needed.

— pH ≤7.35 with PaCO₂ ≥45, OR severe dyspnea with accessory muscle use and paradoxical abdominal motion, OR persistent hypoxemia despite O₂.

Board pearl: NIV reduces intubation, mortality, and length of stay in acute hypercapnic respiratory failure from COPD — it is the single highest-yield intervention after oxygen titration. Absolute contraindications: cardiac/respiratory arrest, inability to protect airway, facial trauma.

CCS pearl: Order pulse oximetry continuous, telemetry, and DVT prophylaxis (enoxaparin 40 mg SC daily) in the admission orders block.

Disposition decision tree:

BAP-65 or DECAF score stratify in-hospital mortality:

Initial therapeutic bundle (the "ABC + S" of exacerbation):

NIV indication thresholds:

Pharmacotherapy — First-Line Drug Regimen

— Albuterol 2.5 mg nebulized q1h × 3, then q4–6h; or MDI 4–8 puffs with spacer.

— Ipratropium 0.5 mg nebulized q4–6h; combine with albuterol (DuoNeb) — additive bronchodilation.

— Hold long-acting muscarinic antagonist (tiotropium) while on scheduled ipratropium to avoid duplication.

— Side effects: tachycardia, tremor, hypokalemia (β-agonist); dry mouth, urinary retention (anticholinergic).

— Prednisone 40 mg PO daily × 5 days (REDUCE trial — no benefit beyond 5 days for most).

— IV methylprednisolone 40–60 mg q6–12h only if NPO, ICU, or NIV-dependent; transition to PO ASAP.

— Monitor glucose (stress hyperglycemia common), mood, infection risk.

— No taper needed for ≤14-day courses.

— Anthonisen type I (all 3 cardinal symptoms), OR type II with purulent sputum, OR requiring mechanical ventilation (invasive or non-invasive).

— 5-day course standard.

— Empiric choice (no Pseudomonas risk): azithromycin, doxycycline, or amoxicillin-clavulanate.

— Pseudomonas risk (FEV₁ <50%, frequent antibiotics/steroids, prior Pseudomonas, bronchiectasis): levofloxacin 750 mg or piperacillin-tazobactam pending cultures.

— Procalcitonin <0.25 ng/mL supports withholding or shortening antibiotics.

— Venturi mask preferred for controlled FiO₂; target SpO₂ 88–92%, PaO₂ 60–70.

— High-flow nasal cannula is reasonable for hypoxemia without significant hypercapnia.

— Magnesium sulfate 2 g IV — modest evidence, consider in severe.

— Mucolytics, methylxanthines (theophylline), chest physiotherapy — not routinely recommended.

Step 3 management: "Prednisone 40 × 5, antibiotics × 5, neb q4h, O₂ 88–92" — memorize this admission order block for COPD exacerbation CCS cases.

Short-acting bronchodilators (cornerstone):

Systemic corticosteroids:

Antibiotics — when to give:

Oxygen therapy:

Adjuncts:

Expanded Pharmacology, NIV, and Invasive Ventilation

— First-line ventilatory support for acute hypercapnic respiratory failure (pH 7.25–7.35, PaCO₂ ≥45).

— Initial settings: IPAP 10–12, EPAP 4–5, titrate IPAP up by 2 q10 min to relieve dyspnea and reduce CO₂; max ~20/8.

— Reassess at 1–2 hours: improvement in pH, RR, and mental status = success; worsening = intubate, do not delay.

— Failure rate ~15–25%; predictors of failure include pH <7.25, GCS <11, severe hypoxemia, copious secretions.

— Indications: NIV failure, inability to protect airway, hemodynamic instability, cardiac/respiratory arrest, severe acidosis pH <7.10 with refractory symptoms.

— Vent strategy: low RR (10–12), prolonged expiratory time (I:E 1:3 or 1:4), low tidal volume (6–8 mL/kg IBW), permissive hypercapnia, monitor for auto-PEEP (intrinsic PEEP).

— If hypotension after intubation → disconnect circuit to allow exhalation (treats auto-PEEP); rule out tension pneumothorax.

— Resume or initiate LABA/LAMA combination (e.g., tiotropium/olodaterol, umeclidinium/vilanterol) once SABA frequency decreased.

— Add ICS (triple therapy) if blood eosinophils ≥300 OR ≥100 with ≥2 moderate/1 severe exacerbation/year.

— Avoid ICS monotherapy in COPD (pneumonia risk without benefit).

— Roflumilast (PDE4 inhibitor): chronic bronchitis, FEV₁ <50%, frequent exacerbations.

— Azithromycin 250 mg daily or 500 mg 3×/week: former smokers with frequent exacerbations on optimal triple therapy — check QTc, baseline LFTs, audiogram.

— Dupilumab (2024 FDA approval): type 2 inflammation phenotype with eos ≥300 despite triple therapy.

Board pearl: NIV + bronchodilators + steroids + targeted antibiotics is the mortality-reducing bundle — every minute of delayed NIV in pH <7.35 increases intubation risk.

Non-invasive ventilation (NIV / BiPAP):

Invasive mechanical ventilation:

Long-acting agents — restart pre-discharge:

Adjunct chronic agents to consider:

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher mortality from exacerbation; lower physiologic reserve.

— Polypharmacy: review for anticholinergic burden (urinary retention with ipratropium + others), benzodiazepines, opioids — all worsen hypercapnia.

— Delirium prevention bundle: orient, mobilize, sleep hygiene, avoid restraints, minimize tethers.

— Fall risk after steroid-induced myopathy and deconditioning — PT/OT consult early.

— Bone health: prednisone bursts cumulatively raise fracture risk; ensure calcium/vitamin D and consider DEXA if multiple courses.

— Levofloxacin and piperacillin-tazobactam require dose adjustment when CrCl <50.

— Avoid NSAIDs (often used inappropriately for pleuritic discomfort).

— Monitor for AKI from contrast (CTPA) — pre-hydrate; do not delay imaging when PE suspected.

— Magnesium clearance reduced; dose cautiously.

— Azithromycin can elevate LFTs; avoid in severe cholestasis.

— Roflumilast contraindicated in moderate-severe hepatic impairment (Child-Pugh B/C).

— Theophylline metabolism reduced — avoid.

— β-agonist tachycardia may worsen demand ischemia or AFib RVR; use cardioselective β-blockers (metoprolol, bisoprolol) — safe and beneficial in COPD with HFrEF.

— Diuresis if volume-overloaded; do not under-diurese for fear of "drying out" — HF and COPD often coexist.

— Anticipate steroid-induced hyperglycemia; initiate sliding scale + basal insulin; hold or reduce sulfonylurea, continue metformin if eGFR allows.

— Educate on transient glucose elevation; arrange close PCP follow-up to taper insulin as steroids stop.

Key distinction: Cardioselective β-blockers are not contraindicated in COPD — withholding them after MI or in HFrEF is a common board trap.

Step 3 management: Reconcile every home med on admission; explicitly note which were held and the plan to resume.

Elderly (≥65) considerations:

Renal impairment:

Hepatic impairment:

Heart failure overlap:

Diabetes:

Special Populations — Pregnancy, Pediatrics, and Other Subgroups

— True COPD in pregnancy is uncommon; more often severe asthma — re-examine diagnosis.

— If COPD exacerbation occurs: albuterol, ipratropium, prednisone, and azithromycin are acceptable in pregnancy.

— Avoid fluoroquinolones (cartilage concerns), tetracyclines (tooth/bone after 18 wk), and roflumilast.

— Maintain maternal SpO₂ ≥95% (higher target than non-pregnant to protect fetal oxygen delivery).

— Multidisciplinary care: pulmonology + MFM.

— Suspect in patients <45, non-smokers with emphysema, lower-lobe predominance, family history, unexplained liver disease.

— Confirm with serum AAT level + phenotyping (Pi typing); ZZ is classic severe.

— Augmentation therapy (IV pooled human AAT, weekly) for PiZZ with FEV₁ 30–65%.

— Counsel on smoking cessation as life-extending, alcohol moderation (liver), family screening.

— ≥2 moderate or ≥1 severe exacerbation/year despite triple therapy.

— Consider azithromycin prophylaxis, roflumilast, dupilumab (eos-high), lung volume reduction surgery or endobronchial valves (selected upper-lobe heterogeneous emphysema, FEV₁ 20–45%).

— FEV₁ <30%, BODE ≥7, hypercapnia, frequent admissions → discuss palliative care, advance directives, lung transplant candidacy (typically <65, BMI <30, BODE 7–10).

Board pearl: A non-smoker under 50 with basilar emphysema and elevated LFTs — check AAT level; counsel siblings on testing.

CCS pearl: On any COPD discharge, document a goals-of-care conversation and palliative referral consideration if frequent exacerbator.

Pregnancy (rare but tested):

α1-antitrypsin deficiency:

Post-lung transplant patients: Exacerbation may herald rejection or infection (CMV, Aspergillus, Pneumocystis) — early transplant team involvement.

Veterans / occupational exposures: Burn pits, silica, coal dust — link to disability benefits and pulmonary rehab referral.

Frequent exacerbator phenotype:

End-stage COPD:

Complications and Adverse Outcomes

— Hypoxemic (type 1): PaO₂ <60 on room air — bronchodilators, controlled O₂, NIV.

— Hypercapnic (type 2): PaCO₂ >45 with acidemia — NIV first-line.

— Mixed picture common in advanced COPD.

— Spontaneous from bullous disease; sudden chest pain + worsening dyspnea + unilateral hyperresonance → urgent CXR or POCUS.

— Tube thoracostomy for symptomatic or >2 cm pneumothorax.

— Hypoxic pulmonary vasoconstriction → RV pressure overload → JVD, edema, hepatic congestion.

— Treat hypoxemia (vasoconstriction reverses), gentle diuresis, avoid systemic vasodilators that worsen V/Q.

— Exacerbation is a transient MI/stroke/AFib trigger — risk peaks in first 7 days.

— Continue or initiate statin, antiplatelet, β-blocker if indicated by comorbidities.

— DVT/PE risk 2–3× elevated during exacerbation — always order pharmacologic prophylaxis (enoxaparin 40 mg SC daily or UFH 5000 q8h).

— Hospital-acquired pneumonia, C. difficile (post-antibiotics), pressure injury, deconditioning.

— Steroid-induced hyperglycemia, psychiatric effects, gastritis.

— In-hospital mortality 4–10%; 1-year mortality post-hospitalization ~25%; 5-year ~50%. Communicate prognosis honestly.

Key distinction: A COPD patient who fails to improve in 48–72 hours on standard therapy — re-image (PE, pneumothorax, pneumonia, effusion) before assuming refractory exacerbation.

Step 3 management: Discharge bundle must include VTE risk reassessment — extended prophylaxis only if persistent risk factors; otherwise stop at discharge.

Acute respiratory failure:

Pneumothorax:

Cor pulmonale / acute RV failure:

Cardiovascular events:

Venous thromboembolism:

Nosocomial issues:

Mortality:

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Severe dyspnea unresponsive to initial ED therapy.

— Mental status changes (confusion, lethargy, coma).

— Persistent or worsening hypoxemia (PaO₂ <40), severe/worsening respiratory acidosis (pH <7.25) despite NIV.

— Need for invasive mechanical ventilation.

— Hemodynamic instability requiring vasopressors.

— Other organ failures: sepsis, renal failure, ischemic complications.

— Frequent exacerbator, failure to wean, suspected alternative diagnosis (bronchiectasis, ILD, malignancy), candidate for advanced therapy (LVRS, valves, transplant).

— Concurrent ACS, new AFib with RVR, decompensated HF, suspected pulmonary hypertension.

— Frequent admissions, declining functional status, hypercapnia despite optimal therapy, frequent ER visits, patient/family ready for goals-of-care discussion.

— Palliative care can coexist with disease-directed care — frame as symptom support, not "giving up."

— RR >30 or <8, SpO₂ <88% despite escalating O₂, GCS drop ≥2, hemodynamic deterioration.

— Sign-out must include code status, NIV tolerance, latest ABG trend, antibiotic day count, steroid day count, and discharge target date.

CCS pearl: When the simulated patient's ABG shows pH 7.22 / PaCO₂ 78 on NIV after 2 hours — transfer to ICU and intubate; the case rewards timely escalation.

Board pearl: Even with DNI status, NIV is appropriate as ceiling of care if patient/family agrees — clarify explicitly in the chart.

ICU transfer criteria:

NIV trial location: Step-down or ICU depending on institution; do not start NIV on a floor without monitored bed and respiratory therapy availability.

Pulmonology consultation:

Cardiology consultation:

Palliative care consult:

Rapid response / code triggers:

Transfer of care safety:

Key Differentials — Same-Category (Pulmonary) Causes

— Younger, allergic history, reversible airflow obstruction, eosinophilia common.

— Same acute treatment (SABA, SAMA, steroids, O₂); higher dose ICS at discharge; avoid LAMA monotherapy.

— Asthma-COPD overlap exists — manage as overlap with LABA+ICS ± LAMA.

— Fever, focal consolidation on CXR, productive cough — overlaps with exacerbation and frequently coexists.

— Treat per CAP guidelines (ceftriaxone + azithromycin or respiratory fluoroquinolone for inpatient non-ICU).

— Chronic copious purulent sputum, hemoptysis, HRCT shows dilated airways.

— Target Pseudomonas empirically in severe; airway clearance therapy (vest, hypertonic saline).

— Sudden onset, pleuritic pain, tachycardia disproportionate to wheeze, unilateral leg swelling, normal CXR.

— CTPA; anticoagulate.

— Acute unilateral decreased breath sounds; CXR or POCUS confirms.

— Bilateral basal crackles, reticular pattern on imaging, lower DLCO; treat with steroids ± immunosuppression — different long-term path.

— New unilateral wheeze, hemoptysis, weight loss, persistent radiographic abnormality — CT and bronchoscopy.

— Subacute weight loss, night sweats, upper-lobe cavitary disease — isolate and obtain AFB smears.

Key distinction: Wheezing is not synonymous with COPD or asthma — "all that wheezes is not asthma." PE, HF (cardiac asthma), foreign body, vocal cord dysfunction, and anaphylaxis all wheeze.

Step 3 management: Always confirm CXR is reviewed before attributing wheeze to COPD on the floor.

Asthma exacerbation:

Community-acquired pneumonia:

Bronchiectasis exacerbation:

Acute pulmonary embolism:

Pneumothorax (especially in emphysematous bullae):

Interstitial lung disease flare:

Lung cancer / airway obstruction:

Tuberculosis or NTM:

Key Differentials — Other-Category (Non-Pulmonary) Causes

— Orthopnea, PND, S3, weight gain, bilateral crackles, elevated BNP, vascular congestion on CXR.

— Often coexists with COPD; diurese with IV loop, continue β-blocker if hemodynamically tolerated.

— Dyspnea can be anginal equivalent in elderly/diabetic; obtain ECG and troponin in every exacerbation.

— Treat MI per ACS pathway — don't withhold antiplatelets/anticoagulation because of "COPD."

— Acute onset wheeze + urticaria/angioedema/hypotension after exposure — IM epinephrine, not just bronchodilators.

— Hb <8 reduces O₂ delivery and exacerbates dyspnea — transfuse if symptomatic and Hb <7–8 per restrictive strategy.

— Compensatory tachypnea ("Kussmaul") may be misread as exacerbation — check ABG and anion gap.

— Exertional syncope, signs of right heart failure without pulmonary congestion — echo and consider right heart catheterization.

— Myasthenic crisis, GBS, ALS — declining vital capacity, paradoxical breathing; check NIF and FVC.

— Diagnosis of exclusion; tachypnea with normal SpO₂ and respiratory alkalosis on ABG.

— Non-selective β-blockers, opioids (CO₂ retention), benzodiazepines, NSAID-induced bronchospasm in aspirin-sensitive disease.

Board pearl: A COPD patient on chronic opioids for back pain presents with somnolence and PaCO₂ of 70 — consider opioid-induced hypoventilation as a contributor; consider naloxone and reconcile prescribing.

CCS pearl: Recheck the med list for sedatives, β-blocker class, and home oxygen flow rate at every admission — common cause of "exacerbation."

Acute decompensated heart failure:

Acute coronary syndrome:

Anaphylaxis:

Anemia:

Metabolic acidosis (DKA, sepsis, salicylate):

Pulmonary hypertension / RV failure:

Neuromuscular weakness:

Anxiety/panic / hyperventilation:

Medication-induced:

Secondary Prevention, Discharge Medications, and Long-Term Plan

— SABA frequency ≤ q4h, off NIV ≥12–24 h, ambulating at baseline, stable ABG/SpO₂ ≥88% on baseline O₂, tolerating PO, understands plan, follow-up arranged.

— Continue steroids to complete 5-day course (prednisone 40 mg daily, no taper).

— Complete antibiotic course (typically 5 days total).

— Resume/initiate inhaled maintenance therapy based on GOLD group:

— Group B/E: LABA + LAMA (umeclidinium/vilanterol or tiotropium/olodaterol).

— Eos ≥300 or eos ≥100 with frequent exacerbations: LABA + LAMA + ICS (triple therapy: fluticasone/umeclidinium/vilanterol).

— Provide SABA (albuterol MDI with spacer) for rescue.

— Educate on inhaler technique — single most missed step; teach-back required.

— Smoking cessation: combine varenicline or bupropion + NRT + behavioral counseling — single most disease-modifying intervention. Start in hospital.

— Long-term oxygen therapy (LTOT): if resting PaO₂ ≤55 mmHg or SpO₂ ≤88%, OR PaO₂ 56–59 with cor pulmonale, polycythemia, or HF — reassess at 60–90 days post-discharge before final qualification (hypoxemia may resolve).

— Vaccinations: influenza yearly, COVID-19 updated, pneumococcal (PCV20 once or PCV15 + PPSV23), RSV (≥60), Tdap, zoster.

— Pulmonary rehabilitation referral within 4 weeks of discharge — reduces readmission and mortality (Class IA).

— Cardiovascular (statin, antiplatelet, β-blocker), bone health (calcium/vit D, DEXA), depression/anxiety screening (PHQ-9), nutrition.

Step 3 management: Pulmonary rehab referral within 4 weeks is a 30-day readmission reducer and the highest-yield discharge intervention to choose on exam.

Confirm discharge criteria met:

Discharge medication bundle:

Adjunctive long-term:

Comorbidity optimization:

Follow-Up, Monitoring, and Rehab/Counseling

— PCP or pulmonologist within 7–14 days post-discharge — reduces 30-day readmission.

— Telephone or telehealth check at 48–72 hours for symptom assessment, med adherence, inhaler technique.

— Repeat at 4–6 weeks for stable assessment, spirometry, oxygen reassessment.

— Quarterly thereafter if frequent exacerbator; biannual if stable.

— 6–12 weeks, supervised exercise + education + breathing techniques + nutrition + psychosocial support.

— Reduces dyspnea, improves QoL, reduces hospitalization — start within 4 weeks of discharge for greatest benefit.

— Symptoms via CAT score or mMRC at each visit.

— Exacerbation frequency log.

— Inhaler technique — re-demonstrate at every visit.

— Spirometry annually once stable.

— Eosinophil trend to guide ICS use.

— SpO₂ at rest and ambulation if on or being weaned off O₂.

— 5 A's (Ask, Advise, Assess, Assist, Arrange) at every encounter.

— Combine pharmacotherapy + counseling; quitlines (1-800-QUIT-NOW), apps, group programs.

— Color-coded green/yellow/red zone with specific symptoms, rescue inhaler dosing, when to start backup prednisone/antibiotics ("rescue pack"), when to call clinician, when to go to ED.

— Screen for depression/anxiety (40–50% prevalence); offer CBT, SSRI; avoid benzodiazepines.

— Caregiver burden assessment; social work for home health, oxygen logistics, transport.

Board pearl: A written COPD action plan + early follow-up + pulmonary rehab reduces 30- and 90-day readmissions — Step 3 favorite combination question.

Step 3 management: Arrange follow-up appointment and pulmonary rehab referral before discharge order is signed — don't leave it to the patient.

Cadence of outpatient follow-up:

Pulmonary rehabilitation:

Monitoring parameters:

Smoking cessation reinforcement:

Action plan (written):

Psychosocial:

Ethical, Legal, and Patient Safety Considerations

— Discuss before respiratory deterioration — patients with severe COPD have predictable trajectory; failure to discuss is an ethical lapse.

— Differentiate DNR vs DNI vs trial of NIV — NIV may be appropriate ceiling of care even when intubation is declined; document explicitly to avoid bedside ambiguity.

— Reaffirm and update at each admission; preferences may evolve.

— Hypercapnic encephalopathy or hypoxemia can impair decision-making capacity — defer non-urgent decisions until corrected, or use surrogate per state hierarchy (spouse → adult child → parent → sibling).

— Document capacity assessment in chart when refusing recommended treatment.

— Required at every visit; failure to counsel is a quality and ethical gap. Use motivational interviewing, not stigma.

— Med reconciliation errors at discharge cause 30-day readmissions — confirm home oxygen flow rate, inhaler list, and that steroid/antibiotic course completion is clearly documented for the PCP.

— Ensure discharge summary reaches PCP within 48 hours.

— Confirm patient has the medications in hand (or pharmacy delivery confirmed) before discharge — not just a prescription.

— Counsel against smoking near O₂ (fire/burn risk); document warning.

— Verify insurance qualification criteria met (PaO₂ ≤55 or SpO₂ ≤88%) — Medicare requires reassessment at 60–90 days.

— Early palliative care in advanced COPD is not withdrawal of care; offering it improves symptom control and is ethically obligatory in frequent exacerbators.

— Suspected elder neglect (missed medications, poor hygiene at admission) — adult protective services referral.

Step 3 management: Always pair "discharge home" with verified med pickup, follow-up scheduled, and code status documented — three boxes that pop up on board stems.

Advance directives and code status:

Capacity assessment:

Smoking cessation counseling:

Transitions of care risks (Step 3 favorite):

Home oxygen safety:

Driving safety: Severe hypoxemia or sedating medications may impair driving — counsel and document.

Palliative integration:

Reportable concerns:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: Mortality-reducing interventions: smoking cessation, LTOT (if hypoxemic), NIV, lung volume reduction (selected), transplant — memorize this list.

Target SpO₂ 88–92% — avoid hyperoxia (CO₂ retention via Haldane effect, V/Q worsening, absorption atelectasis).

Prednisone 40 mg × 5 days — REDUCE trial; no taper for short courses.

NIV first-line for hypercapnic respiratory failure (pH ≤7.35, PaCO₂ ≥45) — reduces intubation and mortality.

Antibiotics if: Anthonisen type I, purulent sputum + 1 other symptom, or any mechanical ventilation.

Pseudomonas risk factors: FEV₁ <50%, frequent antibiotics, prior isolation, bronchiectasis, recent hospitalization.

MAT = COPD-associated arrhythmia — treat hypoxemia and magnesium, not the rhythm primarily.

Eosinophils ≥300 = ICS responder; <100 = avoid ICS (pneumonia risk without benefit).

Pulmonary rehab within 4 weeks of discharge = mortality benefit.

Smoking cessation = the only intervention proven to slow FEV₁ decline.

LTOT criteria: PaO₂ ≤55 or SpO₂ ≤88% at rest, OR PaO₂ 56–59 with cor pulmonale/polycythemia/HF — reduces mortality.

AAT deficiency: test once in every COPD patient.

Cardioselective β-blockers are safe and beneficial — don't withhold for COPD.

DECAF score stratifies exacerbation mortality (Dyspnea, Eosinopenia, Consolidation, Acidemia, AFib).

Vaccinate: influenza, COVID, pneumococcal, RSV, Tdap, zoster.

30-day readmission is the quality metric — reduced by rehab, follow-up <14 days, action plan, med reconciliation.

Dynamic hyperinflation / auto-PEEP — hypotension after intubation → disconnect and exhale.

Permissive hypercapnia on the vent: low RR, long expiratory time.

Frequent exacerbator (≥2 moderate or ≥1 severe/year on triple therapy) → consider azithromycin, roflumilast, dupilumab.

GOLD 2024 groups: A (low symptoms/low risk), B (high symptoms/low risk), E (high risk, ≥2 exacerbations/year or hospitalization).

Triple therapy preferred for Group E with eos ≥300.

Board Question Stem Patterns

— 68-year-old with COPD, RR 28, SpO₂ 86% on 4 L, pH 7.28, PaCO₂ 62. Best next step?

— Answer: Initiate BiPAP + bronchodilators + steroids + antibiotics + controlled O₂.

— Patient not improving after 48 hours of standard therapy. Next step?

— Answer: Re-image (CTPA for PE, CXR for pneumothorax/pneumonia); reconsider diagnosis.

— Newly intubated COPD patient with BP dropping. Most likely cause and intervention?

— Answer: Auto-PEEP — disconnect circuit briefly; consider lower RR, longer expiratory time.

— Which intervention most reduces 30-day readmission?

— Answer: Pulmonary rehab + early follow-up + written action plan + smoking cessation.

— Stable COPD outpatient with PaO₂ 54 on room air. Mortality-reducing therapy?

— Answer: Continuous LTOT (≥15 h/day) — reassess at 60–90 days.

— Patient on LABA-LAMA with 2 exacerbations/year, eos 400. Add what?

— Answer: ICS (triple therapy).

— Chronic bronchitis, FEV₁ 40%, eos 80, on triple therapy. Next step?

— Answer: Roflumilast or azithromycin prophylaxis.

— Lower-lobe predominant emphysema, abnormal LFTs. Diagnostic test?

— Answer: AAT level + Pi phenotype.

— Irregular rhythm with ≥3 P-wave morphologies in COPD exacerbation. Treatment?

— Answer: Treat hypoxemia, correct electrolytes (Mg, K); avoid cardioversion.

— Patient with FEV₁ 22%, third admission in 6 months, declining functional status. Next step?

— Answer: Palliative care consultation + advance directive discussion.

Step 3 management: Recognize these 10 stem archetypes — they cover ~90% of exam permutations.

Pattern 1 — "Wheezing smoker with ABG":

Pattern 2 — "Refractory exacerbation":

Pattern 3 — "Hypotension after intubation":

Pattern 4 — "Discharge planning":

Pattern 5 — "Long-term oxygen":

Pattern 6 — "Inhaler escalation":

Pattern 7 — "Eosinophil-low frequent exacerbator":

Pattern 8 — "Young non-smoker with emphysema":

Pattern 9 — "MAT":

Pattern 10 — "Goals of care":

One-Line Recap

COPD exacerbation management = controlled oxygen (SpO₂ 88–92%), bronchodilators (SABA+SAMA), systemic corticosteroids (prednisone 40 mg × 5 d), antibiotics when indicated, and NIV for hypercapnic acidosis — followed by a structured discharge bundle of triple therapy when indicated, smoking cessation, vaccinations, pulmonary rehab within 4 weeks, written action plan, and follow-up within 7–14 days.

Acute bundle pearl: "O₂ 88–92, neb q4h, prednisone 40 × 5, antibiotics × 5, BiPAP if pH ≤7.35" — the universal admission order set.

Escalation pearl: Mental status decline, pH <7.25, NIV failure, or hemodynamic instability → ICU and intubation with low RR / long expiratory time vent strategy; suspect auto-PEEP if hypotensive — disconnect to exhale.

Mortality-reducing interventions (memorize the short list): smoking cessation, long-term oxygen if PaO₂ ≤55, NIV in acute hypercapnic failure, pulmonary rehab, lung volume reduction (selected), and lung transplantation in eligible end-stage patients.

Discharge-readmission pearl: The single highest-yield Step 3 combination is pulmonary rehab referral + follow-up ≤14 days + verified med reconciliation + written action plan + smoking cessation pharmacotherapy — choose this answer cluster whenever a stem asks how to reduce 30-day readmission.

Differential pearl: When the exacerbation doesn't fit or doesn't improve in 48–72 h, re-image and reconsider PE, pneumothorax, pneumonia, HF, ACS before declaring the patient "refractory."

Ethics pearl: Discuss code status and trial-of-NIV ceilings before the next decompensation — palliative care can run in parallel with aggressive therapy in advanced disease.